The primary objective ofthe Glioma SPORE Career Development Program (CDP) is to attract talented new investigators to translational glioblastoma research. Potential CDP awardees include junior faculty beginning their careers or established faculty members in other fields who wish to redirect their interests and efforts to glioblastoma research. We will establish a comprehensive, system-wide process for solicitation of CDP applications and an expert-based review process to select the most meritorious applicants. The CDP program faculty will consist of a multidisciplinary cohort of experienced, senior mentors for CDP awardees. The CDP will provide limited-duration funding for promising, junior translational investigators who are focused on glioma research. The program will provide support, mentoring and monitoring for CDP awardees. We will establish a monitoring process to measure progress and outcomes of CDP awardees and the CDP program. We will carefully monitor the progress of awardees through clearly enumerated metrics. The CDP will be assessed on an annual basis by the internal and external advisory boards. The CDP will leverage institutional resources to support and enhance the success of the program.
The Career Development Program will provide research support for junior or new investigators in the field of brain tumor research. Through support, mentoring and monitoring it is anticipated that the program will enable awardees to embark on sucessful careers in brain tumor research that will ultimately benefit patients.
|Tateishi, Kensuke; Higuchi, Fumi; Miller, Julie J et al. (2017) The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res 77:4102-4115|
|Liau, Brian B; Sievers, Cem; Donohue, Laura K et al. (2017) Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell 20:233-246.e7|
|Wen, Patrick Y; Chang, Susan M; Van den Bent, Martin J et al. (2017) Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol 35:2439-2449|
|Ni, Jing; Xie, Shaozhen; Ramkissoon, Shakti H et al. (2017) Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol 19:22-30|
|Han, Catherine H; Batchelor, Tracy T (2017) Primary Central Nervous System Lymphoma. Continuum (Minneap Minn) 23:1601-1618|
|Zhang, Jing; Gao, Xueliang; Schmit, Fabienne et al. (2017) CRKL Mediates p110?-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep 20:549-557|
|Zhang, Biqi; Chang, Ken; Ramkissoon, Shakti et al. (2017) Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol 19:109-117|
|Venteicher, Andrew S; Tirosh, Itay; Hebert, Christine et al. (2017) Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 355:|
|Wang, Nancy; Jain, Rakesh K; Batchelor, Tracy T (2017) New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics 14:321-332|
|Speranza, Maria-Carmela; Passaro, Carmela; Ricklefs, Franz et al. (2017) Preclinical investigation of gene-mediated cytotoxic immunotherapy and checkpoint blockade in glioblastoma. Neuro Oncol :|
Showing the most recent 10 out of 63 publications